Genitourinary Cancers | Specialty

Eganelisib/Nivolumab Elicits Promising Responses, PFS Benefit in Metastatic Urothelial Cancer

January 7th 2021

January 7th, 2021 - The addition of eganelisib to nivolumab was found to elicit encouraging responses and improve progression-free survival compared with single-agent nivolumab in patients with platinum-refractory, immunotherapy-naïve, advanced, metastatic urothelial cancer.

Dr. McGregor on the Focus of Future Research Efforts in RCC

January 7th 2021

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Dr. Gupta on Developing Biomarkers of Lack of Response in Urothelial Carcinoma

January 5th 2021

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Telaglenastat Plus Cabozantinib Fails to Improve PFS in Advanced or Metastatic RCC

January 4th 2021

The combination of telaglenastat plus cabozantinib failed to result in a significant improvement in progression-free survival in patients with advanced or metastatic renal cell carcinoma.

Expert Compares Open vs Robotic Radical Cystectomy Approaches in Muscle Invasive Bladder Cancer

January 2nd 2021

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Mian Makes Sense of Multidisciplinary Bladder Preservation Approaches

December 31st 2020

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.

Despite Efforts Made With Immunotherapy in Metastatic Urothelial Cancer, Chemotherapy Remains King in Frontline

December 30th 2020

Shilpa Gupta, MD, discusses ongoing research with immunotherapy in bladder cancer, where research efforts should focus with regard to biomarkers, and other emerging agents that might move the needle forward.

mRCC Risk Assessment and Treatment Options

December 23rd 2020

Preferred treatment regimens that incorporate novel therapies used to treat patients with metastatic renal cell carcinoma based on risk status.

Risk Stratification in Renal Cell Carcinoma

December 23rd 2020

A historical overview regarding the development of parameters used to help stratify risk in patients with renal cell carcinoma and the relevance of current models in the context of selecting systemic therapy to treat appropriate patients.

Dr. Powles on the Rationale to Evaluate ctDNA in High-Risk Muscle-Invasive Bladder Cancer

December 22nd 2020

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

N-803 Plus BCG Elicits 72% CR in BCG-Unresponsive, High-Grade Non-Muscle Invasive Bladder Cancer

December 22nd 2020

December 22, 2020 — Intravesical Bacillus Calmette-Guerin in combination with N-803 was found to induce a complete response rate of 72% in patients with non-muscle invasive bladder cancer in high-risk carcinoma in situ disease, meeting the primary end point of the phase 2/3 QUILT 3.032 trial.

Multimodality Therapy Makes Waves in Bladder Cancer

December 21st 2020

Faculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.

Newly Diagnosed RCC: Treatment Planning

December 18th 2020

Guidelines and recommendations by clinicians on treatment approaches for newly diagnosed renal cell carcinoma and regimens in the pipeline that may impact future treatment.

Supportive Care and Systemic Therapy for RCC

December 18th 2020

Advice to health care providers on when to refer patients for further assessment of potential renal cell carcinoma and insight on the types of diagnostic tests used to help confirm a diagnosis in the era of molecular testing.

Merck to Build New Facility to Meet BCG Demand

December 17th 2020

December 17, 2020 - Merck is set to build a new manufacturing facility to increase its production of TICE Bacillus Calmette–Guérin, tripling its current manufacturing capacity.

Dr. Powles on the Role of ctDNA Positivity in High-Risk Muscle-Invasive Urothelial Cancer

December 15th 2020

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.

Immunotherapy Finds a Foothold in Metastatic Bladder Cancer, But Frontline Challenges Remain

December 14th 2020

The emergence of checkpoint inhibitors has transformed the second-line treatment of patients with metastatic bladder cancer. However, questions regarding the utility of immunotherapy in the frontline setting remain unanswered, leaving chemotherapy as the standard-of-care option.

Emerging Therapies for Relapsed/Refractory MRCC

December 14th 2020

The Future Treatment Landscape of RCC

December 14th 2020

The Role of Combination Treatment in RCC

December 14th 2020